by ecancer reporter Janet Fricker
The first results from the EPIC study provide valuable insights into the influence of food groups and nutrients in gastric cancer, colorectal cancer, lung cancer , breast cancer and prostate cancer, reports the European Journal of Cancer.
The fact that only 5 to 10% of all cancer cases are due to genetic defects, and that 90 to 95 % are due to life style factors led the European Prospective Investigation into Cancer and Nutrition (EPIC) study investigators to explore the relationship between diet and cancer and other chronic diseases.
In the multicentre prospective EPIC study - carried out in 23 centres in 10 European countries - 519,978 volunteers answered self administered questionnaires relating to diet over the previous 12 months. Additional information was collected on habits, lifestyles and medical histories.
Results show:
“In combination with data from other prospective studies, including studies using biological biomarkers, the study contributes to the scientific knowledge for appropriate public health policies and strategies aimed at reducing the global cancer burden,” conclude the authors, led by Carlos Gonzalez from the Institut Catala d’Oncologia (Barcelona, Spain) and Elio Riboli from Imperial College, (London, UK). The study’s strengths, add the authors, include its large size, multiple populations with large variations in the incidence of cancers and wide range of dietary patterns encompassing both Mediterranean diets and those of central and northern European countries.
Reference
C A Gonzalez and E Riboli. Diet and cancer prevention: Contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. European Journal of Cancer 2010. 46, 2555-2562.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.